Why the study?
Does spironolactone 25 mg/d improve exercise tolerance and arterial function in older adults with stable compensated HFpEF?
Does spironolactone 25 mg/d improve exercise tolerance and arterial function in older adults with stable compensated HFpEF?
In older adults with stable HFpEF, 9 months of spironolactone 25 mg/d reduced blood pressure but did not improve exercise capacity, quality of life, or arterial stiffness.
Spironolactone does not improve exercise tolerance or arterial function in older HFpEF patients; reinforces evidence against benefit for diastolic HF.
OBJECTIVES: To evaluate the effects of an aldosterone antagonist on exercise intolerance in older adults with heart failure and preserved ejection fraction (HFpEF). DESIGN: Randomized, placebo-controlled, double-blind trial. SETTING: Academic medical center, Winston-Salem, North Carolina. PARTICIPANTS: Older adults (N = 80, aged 71 ± 1; 80% female) with stable compensated HFpEF and controlled blood pressure (BP). MEASUREMENTS: ), 6-minute walk test, Minnesota Living with Heart Failure Questionnaire (MLHFQ), cardiac magnetic resonance imaging, Doppler echocardiography, and vascular ultrasound. RESULTS: (-8.2% to 3.2%) excluded a clinically significant beneficial effect. There were also no significant differences in 6-minute walk distance, arterial stiffness, left ventricular (LV) mass, LV mass/end-diastolic volume, or MLHFQ score. CONCLUSION: In older adults with stable compensated HFpEF, 9 months of spironolactone 25 mg/d was well tolerated and reduced BP but did not improve exercise capacity, quality of life, LV mass, or arterial stiffness.
No takes yet. Share an insight, caveat, or question.
Upadhya et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: